Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.54 |
| ▸ | CA1 | P00915 | 6/20 | 0.54 |
| ▸ | CA2 | P00918 | 6/20 | 0.54 |
| ▸ | CA7 | P43166 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16606258 | 0.74 | CA12 (0.75) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2656280 | 0.73 | KMT2A (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2658293 | 0.72 | KDM4E (0.77) | CA12CA1CA2CA7CA9 | |
| SCHEMBL851042 | 0.72 | SCN9A (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2659524 | 0.72 | GCK (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1817014 | 0.72 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1179763 | 0.72 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9605443 | 0.72 | CA12 (0.66) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23066461 | 0.71 | CA12 (0.92) | CA12CA1CA2CA7CA9 | |
| SCHEMBL39331 | 0.71 | CA12 (1.00) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102427853-B | Protease Inhibitors | ORION CORP | 2014-11-05 | — | — | CN | disclosed |
| US-20140200225-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2014-07-17 | — | — | US | disclosed |
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| CN-102427853-A | Protease Inhibitors | ORION CORP | 2012-04-25 | — | — | CN | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133748-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009083553-A1 | AZINE COMPOUNDS AS GLUCOKINASE ACTIVATORS | RHEOSCIENCE A/S (DK) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009083553-A1 | AZINE COMPOUNDS AS GLUCOKINASE ACTIVATORS | RHEOSCIENCE A/S (DK) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | CA12 2031/4885CA1 1657/4885CA2 2649/4885 |
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | CA12 2031/4885CA1 1657/4885CA2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.